Journal
BIOMARKERS
Volume 21, Issue 2, Pages 164-167Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/1354750X.2015.1118551
Keywords
diabetic nephropathy; podocyte; urinary podocalyxin; Biomarker
Categories
Funding
- Grants-in-Aid for Scientific Research [16K09229, 26293165] Funding Source: KAKEN
Ask authors/readers for more resources
Diabetic nephropathy has dramatically increased worldwide. In this study, we measured urinary podocalyxin in 240 patients with diabetes. The relationship between urinary podocalyxin and clinical parameters and the effects of dipeptidyl peptidase-4 inhibitors (DPP4i) and alpha-glucosidase inhibitor (a-GI) on urinary podocalyxin levels were examined. Urinary podocalyxin levels were significantly higher in patients with microalbuminuria than in those with normoalbuminuria. Urinary podocalyxin levels were also significantly related to albumin-to-creatinine ratio. Neither DPP4i nor alpha-GI ameliorated the increase in urinary podocalyxin levels. Our results indicated that urinary podocalyxin will be not only an early marker but also a treatment target for DN.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available